Anavex Life Sciences Corporation (AVXL) 옵션

Go to audiobooks.
If that doesn’t work try
paying a tutor.

You were there
AVXL Weekly Logarithmic: https://invst.ly/19sdt1

Or I'm sure your kids, grandkids ,nieces and/or nephews are near experts on those 5 social media platforms.
My friends get annoyed when I contact them via email as that's so last decade, and as another poster suggested, it would take a team of people to monitor incoming emails.

Falconer
How about contacting Wisner Baum or Morgan and Morgan law firms instead. Never know what you’ll get by asking to speak to the
Office Manager to explain your good intentions. Have done it myself to get in touch with some very private people over my career. Check it out here…

RFK Jr. intends to keep financial interest in some lawsuits brought by firm that challenges pharmaceutical companies

Fredreka Schouten
By Fredreka Schouten, CNN
3 minute read
Published 10:51 PM EST, Wed January 22, 2025



President-elect Donald Trump's nominee to be Secretary of Health and Human Services Robert Kennedy Jr. sits in a meeting with Sen. John Cornyn on Capitol Hill on January 9, 2025, in Washington, DC.
President-elect Donald Trump's nominee to be Secretary of Health and Human Services Robert Kennedy Jr. sits in a meeting with Sen. John Cornyn on Capitol Hill on January 9, 2025, in Washington, DC. Jon Cherry/Getty Images
CNN
—
Robert F. Kennedy, Jr. – the vaccine skeptic President Donald Trump has nominated to serve as Health and Human Services secretary – plans to retain his financial interest in some litigation brought by Wisner Baum, a law firm whose specialties include pursuing pharmaceutical drug injury cases.

Ethics records released Wednesday indicate that Kennedy intends to keep collecting fees related to past referrals of clients to the firm, even as he would serve in a position to oversee policies that affect drug makers should the Senate confirm him to the post. Kennedy’s confirmation hearings before two Senate committees are scheduled for next week.

Kennedy’s financial disclosures, filed as part of his potential role in the incoming administration and during his brief run for the presidency last year, show he has earned more than $2.4 million from the Wisner Baum arrangement in recent years.


Wisner Baum is currently suing Merck over Gardasil – which is administered to young people to prevent HPV, the human papillomavirus – with a trial beginning this week in California, according to the firm’s website. Long-lasting infections with certain types of HPV can lead to cancer later in life.

Wisner Baum describes itself as home to the “top Gardasil lawyers in America.”

In his ethics agreement posted Wednesday, Kennedy said he would resign from his consulting arrangement with the firm if he’s confirmed by the Senate. However, he said he was entitled “to receive 10% of fees awarded in contingency cases referred” to Wisner Baum and intended to retain that contingency fee interest in cases that the HHS ethics office determines “do not involve the United States as a party and in which the United States does not have a direct and substantial interest.”

Kennedy pledged to divest his “interest from all pending contingency fee cases that involve claims against the United States, including any claims filed under the National Vaccine Injury Compensation Program,” a reference to the special vaccine court that compensates for injuries.



CNN has reached out to a Kennedy spokesperson and the Department of Health and Human Services.

Kennedy has long sought to sow doubts about the safety and efficacy of vaccines, including Gardasil – which the Centers for Disease Control and Prevention recommends as part of routine vaccinations for children at ages 11 or 12.

In a statement to CNN, Merck said, “An overwhelming body of scientific evidence, including more than 30 years of research and development along with real world evidence generated by Merck and by independent investigators, continues to support the safety and efficacy of our HPV vaccines.”

In his filings Wednesday, Kennedy said he also has a referral agreement with another firm, Morgan & Morgan PA, that entitled him to receive 10% of fees awarded in cases he referred. Kennedy said he has no outstanding contingency fee cases with that firm and would receive no further payment on past cases.

He said he would end his agreement with Morgan & Morgan if confirmed.

CNN’s Meg Tirrell and Aaron Pellish contributed to this report.

Incoherent verbiage..

It is the - "it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail" - analogy to an MBA apply to those skills to pre-revenue biotech investing.

Yes, manufacturing drug is not a concern. Biotech investors are watching trial results and regulatory actions. Ignore silliness.

The MOA of Anavex's drug blarcamesine directly addresses Alzheimer's as a mitochondrial disease (unlike its competitors), which is why it has been successful in its trials.

k9uwa---" Picked Anavex back in 2015."---we have something in common John--I also bought my 1st Anavex shares in 2015---May of that year. With all due respect you really didn't tell most of us here anything we didn't already know in your most recent post !! If you find out when we will get real news from the EMA or details of some kind of partnership do post with your findings !!!! The Best to you !!!!

Anavex themselves and I (for what it is worth) agree that AD is a complex disease that will need a multidimensional approach to prevent and/or successfully treat.

Anavex, if A2-73 if approved, would be one element of that treatment/prevention regimen for some patients, not least because the MoA is addressed at mitochondrial homeostasis and thus the energy ATP cycle.

Obviously for you point, assuming you have one, to become a relevant reality - some treatments would need to be approved for various aspects of e.g. AD for combinations to be identified and prescribed to responders.

This is a position where someone will be hired to essentially oversee contracting pharmacovigilance to an offshore company. The position is consistent with what is needed by any commercial pharma company - what we would expect of a company hoping to launch a product.

Alzheimer is a mitochondrial/energetic disease, and that's why target manipulation by single meds has proven ineffective over and over again & will do so again here!!

Spend too much time making the images work with iHub to correct typos...

"It paints a more detailed picture of ownership style and correctly buckets and excludes holdings that does not belong to Firm and Fund ownership making the total proper institutional ownership 33% of the Free Float.

Note that about 20% of that is Index style.

Anytime I've expected anything from this stock I've been grossly disappointed why should this be any different?

Here is an up-to-date summary overview of Firm and Fund Holdings from my professional financial terminal.

It paints a more detailed picture of ownership style and correctly buckets and excludes holdings that does not belong Firm and Fund ownership maiming the total 33% of the Free Float.

And........one of the speakers on Saturday 19 april, Prof. Marwan Sabbagh, 1:00 PM - 01:20 PM: Emerging Treatments for Alzheimer’s Disease, in https://mco.ae/icadme/agenda/ ; Anavex is sponsor of this event!!

Very, very impressive: https://sigma.larvol.com/company.php?CompanyId=8778&tab=newstrac&page=1

https://www.tealhq.com/job/global-pharmacovigilence-senior-executive-director_c3061a63-f836-4c0a-b1ad-d84b3b8d2968?included_keywords=refresher+training&page=8

The Mysterious Flow of Fluid in the Brain.

https://www.quantamagazine.org/the-mysterious-flow-of-fluid-in-the-brain-20250326/

If that is true maybe Cruz's bill will have a chance to help us, as an end around. That is, if this little planned stockholder campaign doesn't work.

Wouldn't it makes sense to wait until there is an FDA filing before putting on a contact campaign?

That's not how it went down with the EMA, in fact the opposite

But No Useful Email Addresses

Post it to his X account. You can be sure someone in his dept will read it. If compelling, they will bring it to his attention.

Had a little time this evening to look about a bit. Lets see where we stand relative to who owns Anaxex shares.
Fintel says: Institutional Shares (Long) 34,715,010 - 40.81% (ex 13D/G) - change of 1.78MM shares 5.40% MRQ
So whatever their sources are they say we are UP 1.78MM shares which is 5.4% more than the end of year quarter. We do get accurate numbers for end of year on Feb 15th. Yes SEC rules say those institutions have to file 45 days after the end of each quarter. Forms 13F/D/G. Looking a bit more at this info Fintel says:
Institutional Owners 304 total, 295 long only, 0 short only, 9 long/short - change of 11.76% MRQ MRQ = Most Recent Quarter.
So then for some the question is who gives a Hoot how many shares and who else owns AVXL. Well somehow for the most part these "Tutes" maybe know more than those of us who post to Investors Hub. Or maybe we come very close to matching the "Tutes" ability to know what and when to buy what stocks. We are fortunate to have quite a few posters to Ihub who have different methods of finding and posting information. Some great. Some good. Some are maybe BOTS But by reading all you soon learn who really is interested and own shares in AVXL. and the WHY they own those shares. All of us are here hoping to make some $$$ some of us are here because we think that Anavex does have the Magic bullet that won't solve ALZ but for damned sure will greatly slow the advancement of ALZ. Put me in that box. Picked Anavex back in 2015. Time to end this diatribe and get a little sleep. Reference to previous post.
Since I am anything but anonymous if you don't think so just put my moniker into your favorite search engine. Those of us with a federal HamRadio license can not hide.
off for a few hours of ZZZZZZzzzz time.
John k9uwa

It's like high school except the people are anonymous, which makes some people even worse.

LOL not if he includes his autobiography :)

How would prioritizing 2-73 for the USA "screw the EMA"? There is plenty of 2-73 to go around and any country that approves it would see large benefits. If both the EMA and the FDA approve then both Europeans and Americans will benefit, right?

Agree that 2-73 would be a boon both financially and efficacy-wise...but doesn't that require that the new Administration prioritize science over emotion? It is possible that the Trump administration WILL move to approve 2-73 expeditiously but I still haven't read anything that makes a case for why that would happen other than wishful thinking.

Bunch of garbage!

No worries! I don’t post much here anymore. Social Media everywhere, has been corrupted by so many unscrupulous people.

i forgot to mention that we can expect topline data from the Phase 2 trial using Anavex 3-71 as a treatment for schizophrenia by or before June 30, 2025.

The OLE (open label extension) study results for the Alzheimer’s blarcamesine study will be released next week!!!

The 120 day stop #1 for the EMA questions should be received by the end of April 2025!!!

The 2nd quarter fiscal results should be released during a teleconference that will include a question and answer section regarding updates on activities around the first week of May 2025!!!

There should be an annual shareholders meeting ASM around the middle of June 2025!!!

Good luck and GOD bless,

It's their media...I would just request if they can forward an email to RFK Jr...Or provide an email that could help you...It doesn't hurt to try.

They will look at the safety aspects. Blarcamesine is the number 1 safest CNS drug ever developed to this day in over 10 years of proven drug trial results and endorsed by 58 of the best doctor / scientist in the world through peer review study. Winner. imo

I don't think the FDA is on board.
They've looked the fool in the Alzheimer's space lately.
I think Dr. Missling is doing an end around and will let peer pressure do the work for him.

Point made. I think the AD advocacy groups will be exerting a fair amount of pressure once the NDA is filed.

Sure would be a good thing to get that filed. Anavex maybe waiting to get past the initial clock stop and being sure that the questions are satisfactorily answered before filing. That would allow Anavex to address any issues raised by CHMP in the NDA filing and hopefully enhance the chances of approval.

Sounds like you will save yourself the embarrassment 👌

To Whom?
You can send it here...OCRMedia@hhs.gov
Thanks. HHS is the right government agency. But I looked around, can't find who or what this email goes to? What is the position or duty of the person who opens emails with this email address? What or who is "OCRMedia?"

Important to know. My email has to address and say exactly the right things from the first word. I need to know who will be reading my email (and its attached Anavex Life Science Corp Medical Science PDF report I'll create). Otherwise, the PDF gets dumped off by a low-level functionary into the file "Strange and Questionable Emails;" unread and internally unshared.

***********
Not useful. Just found that this email is Office for Civil Rights of HHS.

Still looking for a way to email my PDF to proper, high-level HHS officials.

In advertising they used to say you have to see something 7 times before you'll act, so I see no harm in planting a seed.

nice overlay, Citrati...thanks for the visual comparison

It's all magical thinking, and it's not confined to the FDA.

Wouldn't it makes sense to wait until there is an FDA filing before putting on a contact campaign?

I will give you a possible answer to your question about why would today's FDA care about Blarcamisine. Because the entire Trump administration is transactional and if they can see a way to screw the EMA and bring forth the only drug that can save the govt. billions of $$$$ with no side effects they will do it. I hope that Anavex can make some headway in Washington. Maybe that is why Nell was there last week. I hope she was there with others like Missling and team but that might be asking for too much. But if they can get an audience with the right people ie. RFK jr. and tell the story about the greatest data ever seen for an Alzheimer's drug with no side effects , maybe they can get us a fast track designation and beat the EMA to approval. They got Covid approved pretty quick, why not Alz.

He may not believe in any medications, regardless of studies. The most effective medications in human history - vaccines - apparently mean nothing to him. He just fired the head of the FDA's vaccines group. What makes anyone here hopeful that this Administration would "believe in" 2-73? Serious question, not political. I just don't understand why anyone thinks an FDA that no longer leads with science would be good for Anavex. Can anyone who is hopeful please explain? TIA.

You can send it here...OCRMedia@hhs.gov

The OLE (open label extension) study results for the Alzheimer’s blarcamesine study will be released next week!!!

The 120 day stop #1 for the EMA questions should be received by the end of April 2025!!!

The 2nd quarter fiscal results should be released during a teleconference that will include a question and answer section regarding updates on activities around the first week of May 2025!!!

There should be an annual shareholders meeting ASM around the middle of June 2025!!!

Good luck and GOD bless,

But No Useful Email Addresses
"This is RFK’s contact page, with all of his social media contacts."
Of course, those were the publicly-listed contacts for RFK Jr., which I first checked to find a useful email address that would get a message to RFK Jr's desk, or to someone working closely with him, an office aide, etc.

But, no email addresses for anyone at either of the organizations; merely generic snail mail addresses to the organizations.

If ever I can get a valid email address that connects to someone close to RFK Jr. I'll send my detailed PDF which will tell how FDA approval of blarcamesine will be so helpful. But, understandably, no such email addresses are publicly available. Too much junk would be generated that would clog the administrative works of HHS.

I'll wait to see if I can learn of an appropriate recipient's email address. With that, I'll construct the detailed PDF that will clearly tell the story of Anavex science and how, when implemented, it will transform 21st-century medical care and therapies.

What is the number one reason new drugs fail in the CNS space? It's the safety of the drug fails for all sorts of reasons. What does Blarcamesine bring that no other CNS drug "ever" has? Blarcamesine brings the safest profile drug with over 10 years of proven drug trial results. That is reason alone it will be approved at the EMA. That doesn't even take in consideration all the proven positives it brings. Blarcamesine is a block buster drug in the making. Imo.

I asked my wife to look into this.
Hope it helps.

"This is RFK’s contact page, with all of his social media contacts. If the guy makes a good explanation one of these contacts should work. I would suggest he bombard all of the contact points. I would also suggest he work in the words “Make America Healthy Again” and outline his main points in the post as well as including his PDF."



https://www.hhs.gov/about/leadership/robert-kennedy.html

https://www.mahaaction.com/

IF one looks at AVXL relative to sector movement (XBI) for the last month, AVXL has done very well.
XBI is the solid thick black line.

https://investorshub.advfn.com/uimage/uploads/2025/3/29/iljlnScreen_Shot_2025-03-29_at_9.10.16_AM.png

Hopefully, there will be a press release on Monday April 7, 2025 that will include the PowerPoint presentation from the conference.

Unless someone is planning on attending the conference, I believe that is the best we can hope for.

Good luck and GOD bless,

Sat.April 5--OLE Attention Study---any way we can listen to this Presentation ????? TIA

🤩.....yes, hope so!